Iconix Enters Chemogenomics Relationship with Taisho Pharmaceutical Co., Ltd.

DrugMatrix(R) to Support Taisho's Drug Discovery Activities

16-Jun-2004

Mountain View. Iconix Pharmaceuticals, Inc. today announced that Taisho Pharmaceutical Co., Ltd. will engage Iconix to perform a preliminary chemogenomics profiling and analytical study for a compound in its drug discovery pipeline.

Under the agreement, Taisho will apply Iconix's DrugMatrix(R) platform, a large-scale chemogenomics reference database and informatics system, to enhance drug candidate selection and optimization. Taisho will also explore integrating Iconix's in vivo and in vitro chemogenomics technology into its current processes and key drug discovery efforts.

In addition, Iconix will use biomarkers of drug pathology and mechanism from its Drug Signature(TM) library, the largest collection of predictive biomarkers in the pharmaceutical industry, to profile select leads from Taisho's growing number of compounds. Drug Signatures are derived by Iconix from DrugMatrix.

"The use of chemogenomics supports increased productivity at pharmaceutical companies by allowing them to get better information, sooner," said Jim Neal, CEO of Iconix. "In working with Taisho, Iconix is leading the way to bring the power of genomics-based early toxicology profiling and technology to the Japanese pharmaceutical industry." Financial terms of the deal were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances